TRIM21 and Fc-engineered antibodies: decoding its complex antibody binding mode with implications for viral

Johannes Reusch1, Linda Elise Franken2, Jakob Then1

  • 1Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Munich, Roche Diagnostics GmbH, Penzberg, Germany.

PubMed
Summary

The E3 ubiquitin ligase TRIM21 binds antibodies to degrade viruses. Its novel dual-site binding mechanism enhances viral neutralization and offers new therapeutic strategies.